Skip to main content
Top
Published in: International Journal of Hematology 5/2020

01-11-2020 | Graft-Versus-Host Disease | Original Article

Overcoming barriers for the establishment of a consolidated hematopoietic cell transplantation program in a developing country

Authors: Monica M. Rivera-Franco, Eucario Leon-Rodriguez

Published in: International Journal of Hematology | Issue 5/2020

Login to get access

Abstract

The first hematopoietic cell transplantation (HCT) in Mexico was performed at our institution; however, outcomes were suboptimal the following years, until 1998, when a consolidated HCT was established. The aim of this study was to describe the barriers and the implemented strategies to establish a successful HCT program at a referral center in Mexico and to analyze the outcomes. Barriers were detected based on the results from 1980 to 1997. For the analysis of outcomes, a retrospective study was performed including consecutive patients undergoing autologous, allogeneic, and haploidentical HCT. From November 1998 to December 2018, 363 HCTs were performed (autologous, 59%) in 323 patients. Overall non-relapse mortality (NRM) in autologous and allogeneic HCT was 2% and 14%, respectively. The 5-year overall survival was 71% and 57% for autologous and allogeneic HCT, respectively. The cost of the medications was one of the main limitations for the patients and was successfully overcome by the creation of the non-governmental organization “Unidos”. NRM was diminished after reducing the BuCy2 regimen along with the use of bone marrow. Our results highlight that the implementation of unique strategies at our center, led HCT to represent a financially viable and feasible procedure with optimal results.
Literature
2.
go back to reference Knaul FM, Arreola-Ornelas H, Mendez O. Financial protection in health: Mexico, 1992 to 2004. Salud Publica Mex. 2005;47:430–9.CrossRef Knaul FM, Arreola-Ornelas H, Mendez O. Financial protection in health: Mexico, 1992 to 2004. Salud Publica Mex. 2005;47:430–9.CrossRef
3.
go back to reference Frenk J, Gonzalez-Pier E, Gomez-Dantes O, Lezana MA, Knaul FM. Comprehensive reform to improve health system performance in Mexico. Lancet. 2006;368:1524–34.CrossRef Frenk J, Gonzalez-Pier E, Gomez-Dantes O, Lezana MA, Knaul FM. Comprehensive reform to improve health system performance in Mexico. Lancet. 2006;368:1524–34.CrossRef
4.
go back to reference Limón Flores JA. El trasplante de células hematopoyéticas en México. Una perspectiva desde la III Jornada Académica de Trasplante Hematopoyético en el IMSS de Puebla. Rev Hematol Mex. 2018;19(2):101–4. Limón Flores JA. El trasplante de células hematopoyéticas en México. Una perspectiva desde la III Jornada Académica de Trasplante Hematopoyético en el IMSS de Puebla. Rev Hematol Mex. 2018;19(2):101–4.
5.
go back to reference Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51(6):786–92.CrossRef Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51(6):786–92.CrossRef
6.
go back to reference Majhail NS, Omondi NA, Denzen E, Murphy EA, Rizzo JD. Access to hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2009;16(8):1070–5.CrossRef Majhail NS, Omondi NA, Denzen E, Murphy EA, Rizzo JD. Access to hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2009;16(8):1070–5.CrossRef
7.
go back to reference Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, et al. Worldwide network for blood and marrow transplantation recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources, part II: clinical, technical, and socioeconomic considerations. Biol Blood Marrow Transplant. 2019; pii: S1083–8791(19)30235–6. Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, et al. Worldwide network for blood and marrow transplantation recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources, part II: clinical, technical, and socioeconomic considerations. Biol Blood Marrow Transplant. 2019; pii: S1083–8791(19)30235–6.
8.
go back to reference Das K, Khanna T, Agrawal N. Establishing hematopoietic stem cell transplant unit in resource limited setting: a critical analysis of Indian council of medical research 2017 guidelines. J Transplant. 2018;2018:1292307.CrossRef Das K, Khanna T, Agrawal N. Establishing hematopoietic stem cell transplant unit in resource limited setting: a critical analysis of Indian council of medical research 2017 guidelines. J Transplant. 2018;2018:1292307.CrossRef
9.
go back to reference Yeh AC, Khan MA, Harlow J, Biswas AR, Akter M, Ferdous J, et al. Hematopoietic stem-cell transplantation in the resource-limited setting: establishing the first bone marrow transplantation unit in Bangladesh. J Glob Oncol. 2018;4:1–10.PubMed Yeh AC, Khan MA, Harlow J, Biswas AR, Akter M, Ferdous J, et al. Hematopoietic stem-cell transplantation in the resource-limited setting: establishing the first bone marrow transplantation unit in Bangladesh. J Glob Oncol. 2018;4:1–10.PubMed
10.
go back to reference Rivera Franco MM, Leon RE. Importance of non-governmental organizations for the establishment of a successful hematopoietic stem cell transplantation program in a developing country. J Glob Oncol. 2018;4:1–8.PubMed Rivera Franco MM, Leon RE. Importance of non-governmental organizations for the establishment of a successful hematopoietic stem cell transplantation program in a developing country. J Glob Oncol. 2018;4:1–8.PubMed
11.
go back to reference Leon Rodriguez E, Rivera Franco MM, Perez Alvarez SI. Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant related mortality in allogeneic HSCT. Ann Hematol. 2017;96(9):1525–31.CrossRef Leon Rodriguez E, Rivera Franco MM, Perez Alvarez SI. Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant related mortality in allogeneic HSCT. Ann Hematol. 2017;96(9):1525–31.CrossRef
12.
go back to reference Leon Rodriguez E, Rivera Franco MM, Campos CA. Is Day +1 omission of methotrexate associated with higher incidence of acute graft-versus-host-disease in hematopoietic stem transplantation? Bone Marrow Transplant. 2017;52(5):772–4.CrossRef Leon Rodriguez E, Rivera Franco MM, Campos CA. Is Day +1 omission of methotrexate associated with higher incidence of acute graft-versus-host-disease in hematopoietic stem transplantation? Bone Marrow Transplant. 2017;52(5):772–4.CrossRef
14.
go back to reference Leon Rodriguez E, Rivera Franco MM. Outcomes of hematopoietic stem cell transplantation at a limited-resource center in Mexico are comparable to those in developed countries. Biol Blood Marrow Transplant. 2017;23(11):1998–2003.CrossRef Leon Rodriguez E, Rivera Franco MM. Outcomes of hematopoietic stem cell transplantation at a limited-resource center in Mexico are comparable to those in developed countries. Biol Blood Marrow Transplant. 2017;23(11):1998–2003.CrossRef
15.
go back to reference Rivera Franco MM, Leon Rodriguez E, Castro Saldaña HL. Costs of hematopoietic stem cell transplantation in a developing country. Int J Hematol. 2017;106(4):573–80.CrossRef Rivera Franco MM, Leon Rodriguez E, Castro Saldaña HL. Costs of hematopoietic stem cell transplantation in a developing country. Int J Hematol. 2017;106(4):573–80.CrossRef
Metadata
Title
Overcoming barriers for the establishment of a consolidated hematopoietic cell transplantation program in a developing country
Authors
Monica M. Rivera-Franco
Eucario Leon-Rodriguez
Publication date
01-11-2020
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 5/2020
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02956-0

Other articles of this Issue 5/2020

International Journal of Hematology 5/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine